Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) EBIT (2023 - 2025)

Tonix Pharmaceuticals Holding has reported EBIT over the past 3 years, most recently at -$48.3 million for Q4 2025.

  • Quarterly results put EBIT at -$48.3 million for Q4 2025, down 114.8% from a year ago — trailing twelve months through Dec 2025 was -$125.7 million (up 8.05% YoY), and the annual figure for FY2025 was -$125.7 million, up 8.05%.
  • EBIT for Q4 2025 was -$48.3 million at Tonix Pharmaceuticals Holding, down from -$33.1 million in the prior quarter.
  • Over the last five years, EBIT for TNXP hit a ceiling of -$15.6 million in Q3 2024 and a floor of -$77.3 million in Q2 2024.
  • Median EBIT over the past 3 years was -$28.2 million (2023), compared with a mean of -$31.7 million.
  • Biggest five-year swings in EBIT: plummeted 166.59% in 2024 and later skyrocketed 63.4% in 2025.
  • Tonix Pharmaceuticals Holding's EBIT stood at -$27.3 million in 2023, then rose by 17.74% to -$22.5 million in 2024, then tumbled by 114.8% to -$48.3 million in 2025.
  • The last three reported values for EBIT were -$48.3 million (Q4 2025), -$33.1 million (Q3 2025), and -$28.3 million (Q2 2025) per Business Quant data.